Jason Goldman on Muck Rack

Jason Goldman

San Francisco
As seen in: Medium, The New York Times, Nature, The Guardian, Gizmodo, PLOS ONE, MDPI, Scientific American, Medscape, Daily Business Review and
I work on Internet text boxes with mixed results. Examples include: Blogger, Google, Twitter, Obvious, Medium, the Obama White House.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jason

Contact Jason, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Even With CDC Suppressing COVID-19 Vaccine Data, Clinicians Advocate for Their Value

|
By Pruthvi Patel, John Parkinson , Jason Goldman
| Contagion Live
This is part of a short series with leaders of medical professional organizations to gain insights around the revised Advisory Committee on Immunization Practices (ACIP) charter, as well as commentary around the federal government’s suppression of COVID-19 vaccine data.
Open in Who Shared Issue with article?

Combining Technology and Novel Educator Touchpoints to Enable Greater Hepatitis C Screening

|
By Jason Goldman, John Parkinson , Robert H. Hopkins Jr., MD
| Contagion Live
Hepatitis C continues to pose a major public health challenge in the United States, with millions of individuals living with chronic infection. One of the biggest challenges is that many individuals remain undiagnosed due to low screening rates and the disease’s often silent progression. As health systems look for ways to improve detection and linkage to care, new approaches that combine technology with patient-centered outreach are gaining traction.
Open in Who Shared Issue with article?

CIRCE Study Highlights Cefiderocol’s Activity Against Highly Resistant Gram-Negative Infections

|
By Jason Goldman, John Parkinson , Robert H. Hopkins Jr., MD
| Contagion Live
Emerging real-world evidence from the CIRCE study is shedding new light on the clinical utility of cefiderocol in tackling some of the most challenging antimicrobial-resistant infections. In patients with metallo-beta-lactamase (MBL)-producing carbapenem-resistant Enterobacterales (CRE), the study reported a 68% clinical cure rate at day 14 and an 83% survival rate at day 28—encouraging outcomes in a population historically associated with high mortality and few effective treatment options.
Open in Who Shared Issue with article?
See all 63 licensed articles (69 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Jason

Contact Jason, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified